Fig. 4From: Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective studyStratified analysis of PFS in patients of PD-1 group or PD-L1 group. A: In PD-1 group, locoregional thoracic radiotherapy was related with better PFS; B-C: In PD-L1 group, liver metastases and locoregional thoracic radiotherapy were related with better PFSBack to article page